Show simple item record

dc.contributor.authorGalasso, Gennaro
dc.contributor.authorMirra, M.
dc.contributor.authorDe Luca, G.
dc.contributor.authorPiscione, Federico
dc.date.accessioned2019-11-07T14:54:51Z
dc.date.available2019-11-07T14:54:51Z
dc.date.issued2016
dc.identifier.citationGalasso G, Mirra M, De Luca G, Piscione F. Bivalirudin in patients undergoing pci: state of art and future perspectives. Translational Medicine @ UniSa 2016, 14(9): 57-66it_IT
dc.identifier.issn2239-9747it_IT
dc.identifier.urihttp://elea.unisa.it:8080/xmlui/handle/10556/3785
dc.identifier.urihttp://dx.doi.org/10.14273/unisa-2007
dc.description.abstractAcute coronary syndrome (ACS) represents the most common cause of death worldwide. Percutaneous coronary intervention (PCI) is the management of choice in patients with ACS and occurrence of intra procedural thrombotic complications are an independent predictor of mortality and other major adverse cardiovascular events in patients undergoing PCI. According to current guideline, anticoagulation therapy is indicated during PCI in order to reduce the risk of thrombotic complications such as stent thrombosis. Among currently available anticoagulant drugs, bivalirudin demonstrates a lower incidence of bleeding risk, despite it is associated with an increased risk of stent thrombosis. The aim of this paper is to discuss the pharmacology of bivalirudin and the clinical evidences of its use in patients undergoing PCI for ACS.it_IT
dc.format.extentP. 57-66it_IT
dc.language.isoenit_IT
dc.sourceUniSa. Sistema Bibliotecario di Ateneoit_IT
dc.subjectBivalirudinit_IT
dc.subjectAnticoagulantit_IT
dc.subjectPercutaneous coronary interventionit_IT
dc.subjectMyocardial infarctionit_IT
dc.subjectBleedingit_IT
dc.titleBivalirudin in patients undergoing pci: state of art and future perspectivesit_IT
dc.typeJournal Articleit_IT
 Find Full text

Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record